And a biotechnology enterprise based on bispecific antibody therapy for senile eye diseases
Wuhan Youziyou Biopharmaceutical Co., Ltd. is a biotechnology company dedicated to developing bisspecific antibody (BsAb) based therapies for the treatment of cancer-related complications, cancer and senile eye diseases to address medical needs in the field of oncology and geriatric ophthalmology。The company's mission is to develop innovative medicines to safeguard human health。
Since its establishment in 2010, Youzhiyou Biology has adhered to independent innovation, layout and deep cultivation in the field of bisspecific antibodies, and developed four innovation platforms, including self-developed YBODY®Platform, Check-BODY platform and Nano-YBODYTMPlatform and UVAX developed in cooperation with Wuhan Institute of Virology®Platform, the company has designed and developed seven clinical stage drug candidate pipelines。
-
4 大Innovation platform
-
80 %R&d personnel
-
78 项Patents (33 granted, 45 under review)
Dr. Zhou Pengfei, co-founder, Chairman and Chief Executive Officer, is responsible for the overall strategic planning of the Group and the management of the supervisory and regulatory business。Dr. Zhou received his Bachelor's degree in Pediatrics and his Master's degree in Pediatric Surgery (Oncology) from Tongji Medical University in June 1989 and June 1994, respectively。He received his Doctor of Medicine degree from McMaster University in November 2005。
Dr. Zhou has over 33 years of experience in the healthcare and pharmaceutical industries, including working for Schering-Plough Corporation, Sino-US Crown Biology and other leading companies in the field of tumor biology and tumor immunotherapy。
Dr. Zhou is currently a visiting professor of Tongji Medical College of Huazhong University of Science and Technology and a visiting professor of Central South University。
Dr. Yang Bin, currently Vice President of the Production Center, is responsible for implementing the Group's technology development and product manufacturing strategies and objectives。Dr. Yang received a Bachelor's degree in Pharmacy from Wuhan University and a doctorate degree in biomedicine from Jinan University。
Prior to joining Youzhiyou Biology, Dr. Yang served as Director of monoclonal antibody Department and deputy Director of Research Institute in Shenzhen Dongguang Industrial Development Co., LTD and its subsidiary (Dongguang Group)。
Jing Zhang has served as our Supervisor since February 2018。Mr. Zhang joined the Group in January 2011 and has successively served as Senior Research Assistant of the Company's R&D Center, Senior Manager of the Company's Cell Line Development Department and Director of the Company's R&D Center。In May 2023, he was promoted to Senior Director of the Company's Research and Development Center, where he is responsible for overseeing operational and financial activities and leading the research and development Center。
Prior to joining the Group, Mr. Zhang served as a research assistant at the Institute of Biophysics, Chinese Academy of Sciences from August 2008 to December 2010。He has been a supervisor of Wuhan Huiyou Juyou Enterprise Management Co., LTD., since June 2022。
Mr. Zhang received a bachelor's degree in biotechnology from the School of Life Sciences of Wuhan University and a Master's degree in Biochemistry and Molecular Biology from the Graduate School of the Chinese Academy of Sciences。
Dr. Shaoyi Huang, currently Senior Director of Clinical Division, is responsible for academic support of the Company's clinical programs and the development of policies and management processes related to clinical research。
Dr. Huang has rich experience in clinical research and product development. From March 2014 to July 2020, Dr. Huang served as the Deputy Director of the Oncology Department of Wuhan Youzhiyou Medical Technology Co., LTD., responsible for research and development and clinical work。
Dr. Huang received his Bachelor's degree in Biotechnology and Master's degree in Microbiology from Wuhan University in June 2001 and December 2004 respectively。He received his Ph.D. in cancer biology from the University of Texas Health Science Center at Houston and the University of Texas M.D. Anderson Cancer Center in August 2013。
-
Dr. Zhou Pengfei, co-founder, Chairman and Chief Executive Officer, is responsible for the overall strategic planning of the Group and the management of the supervisory and regulatory business。Dr. Zhou received his Bachelor's degree in Pediatrics and his Master's degree in Pediatric Surgery (Oncology) from Tongji Medical University in June 1989 and June 1994, respectively。He received his Doctor of Medicine degree from McMaster University in November 2005。
Dr. Zhou has over 33 years of experience in the healthcare and pharmaceutical industries, including working for Schering-Plough Corporation, Sino-US Crown Biology and other leading companies in the field of tumor biology and tumor immunotherapy。
Dr. Zhou is currently a visiting professor of Tongji Medical College of Huazhong University of Science and Technology and a visiting professor of Central South University。
-
Dr. Yang Bin, currently Vice President of the Production Center, is responsible for implementing the Group's technology development and product manufacturing strategies and objectives。Dr. Yang received a Bachelor's degree in Pharmacy from Wuhan University and a doctorate degree in biomedicine from Jinan University。
Prior to joining Youzhiyou Biology, Dr. Yang served as Director of monoclonal antibody Department and deputy Director of Research Institute in Shenzhen Dongguang Industrial Development Co., LTD and its subsidiary (Dongguang Group)。
-
Jing Zhang has served as our Supervisor since February 2018。Mr. Zhang joined the Group in January 2011 and has successively served as Senior Research Assistant of the Company's R&D Center, Senior Manager of the Company's Cell Line Development Department and Director of the Company's R&D Center。In May 2023, he was promoted to Senior Director of the Company's Research and Development Center, where he is responsible for overseeing operational and financial activities and leading the research and development Center。
Prior to joining the Group, Mr. Zhang served as a research assistant at the Institute of Biophysics, Chinese Academy of Sciences from August 2008 to December 2010。He has been a supervisor of Wuhan Huiyou Juyou Enterprise Management Co., LTD., since June 2022。
Mr. Zhang received a bachelor's degree in biotechnology from the School of Life Sciences of Wuhan University and a Master's degree in Biochemistry and Molecular Biology from the Graduate School of the Chinese Academy of Sciences。
-
Dr. Shaoyi Huang, currently Senior Director of Clinical Division, is responsible for academic support of the Company's clinical programs and the development of policies and management processes related to clinical research。
Dr. Huang has rich experience in clinical research and product development. From March 2014 to July 2020, Dr. Huang served as the Deputy Director of the Oncology Department of Wuhan Youzhiyou Medical Technology Co., LTD., responsible for research and development and clinical work。
Dr. Huang received his Bachelor's degree in Biotechnology and Master's degree in Microbiology from Wuhan University in June 2001 and December 2004 respectively。He received his Ph.D. in cancer biology from the University of Texas Health Science Center at Houston and the University of Texas M.D. Anderson Cancer Center in August 2013。
The predecessor of the company, Wuhan Youzhiyou Biopharmaceutical Co., Ltd. was established
BsAb platform started development
Development of M802 started
Filed a PCT patent application for "bispecific antibody" to protect YBODY®平台
YBODY®The platform's patent protection in the United States has been expanded to 35 targets
The M701 became the second BsAb in China to file an IND
Establish the Check-BODY platform
M802 China patent granted protection
Build the Nano-YBODY platform
YBODY®The platform's CD3 and HER2 dual-target antibody patents are granted protection in the United States
Completed Series B financing(1)The total amount of funds raised is about RMB 168.Seven million
The rrMM clinical trial application for Y150 was approved by IND of China State Drug Administration
The Y101D clinical trial application has received IND approval from the US FDA for the treatment of solid tumors
Y2019 clinical trial application was approved by IND of China State Drug Administration
Initiating a Phase II MA trial of M701 monotherapy in combination with systemic therapy in patients with EPCAM-positive tumors in China
The Phase Ib/II clinical trial of M701 in the treatment of MPE was approved by IND in China
Entered into an asset transfer agreement with Kang Zhewei Sheng for Y400
Obtained IND approval for Y101D in combination with gemcitabine and albumin-paclitaxel in a Phase Ib/II clinical trial in China as a first-line treatment for patients with pancreatic cancer
Obtained IND approval for Y101D in combination with bevacizumab in a Phase Ib/II clinical trial for HCC and other advanced solid tumors in China
Received IND approval for Y332 for the treatment of metastatic or locally advanced solid tumors
Obtained IND approval for Y400 for the treatment of wAMD and DME
-
Contact number:027-82668988 -
Company Email:info@saramaliahatfield.com -
邮编：430075 -
地址：East Lake New Technology Development Zone, Wuhan City, Hubei Province
Building C2-1, Optics Valley Bio City, 666 Gaoxin Avenue -
传真：027-68788819 -
Business cooperation Contact:BD@saramaliahatfield.com
Email: info@saramaliahatfield.com
Add: Building C2-1, Optics Valley Biologic City, No. 666 Gaoxin Avenue, East Lake New Technology Development Zone, Wuhan City, Hubei Province
